---
schema_version: "secwatch.filing_event.v1"
accession: "0001396814-24-000026"
form_type: "8-K"
ticker: "PCRX"
cik: "0001396814"
company_name: "Pacira BioSciences, Inc."
filed_at: "2024-02-29T23:59:59+00:00"
generated_at: "2026-06-05T06:28:18.782668+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Pacira BioSciences: FY2023 revenue $675M (+1% YoY), net income $42M; CFO to leave Sept 30

## Summary
- Q4 revenue $181.2M (+5% YoY), GAAP net income $24.9M ($0.54 basic EPS), adj EBITDA $65.4M.
- Full-year 2023 total revenue $675.0M (+1% YoY), GAAP net income $42.0M ($0.91 basic EPS), adj EBITDA $214.5M.
- CFO Charles Reinhart to depart effective Sept 30, 2024; transition services through June 2025; search for successor underway.
- 2024 guidance: total revenue $680M-$705M; non-GAAP gross margin 74%-76%; R&D $70M-$80M; SG&A $245M-$265M.
- FDA approved new 200L EXPAREL manufacturing suite in Feb 2024; expects commercial product later this year to benefit gross margins.

## SEC filing metadata
- accession: 0001396814-24-000026
- form_type: 8-K
- ticker: PCRX
- cik: 0001396814
- company_name: Pacira BioSciences, Inc.
- filed_at: 2024-02-29T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/0001396814-24-000026-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/pcrx-20240226.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001396814-24-000026
- JSON: https://secwatch.observer/filing/0001396814-24-000026.json
- Plain text: https://secwatch.observer/filing/0001396814-24-000026.txt

## Key facts
- Earnings Releases
  Pacira BioSciences, Inc. reported fourth quarter and full-year ended December 31, 2023 results: revenue $675.0 million, net income $42.0 million, EPS $0.91 per basic share and $0.89 per diluted share.
  - Period: fourth quarter and full-year ended December 31, 2023
  - Revenue: $675.0 million
  - Net income: $42.0 million
  - EPS: $0.91 per basic share and $0.89 per diluted share
  - Result: reported results
  source text: a filing. --- EX-99.1 (EX-99.1) --- NEWS RELEASE FOR IMMEDIATE RELEASE Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results — Record revenues of $675 million in 2023 — — Full-year GAAP net income of $42 million and adjusted EBITDA of $214 million — — EXPAREL surpasses the 14 million patient mark — — Conference call today at 8:30 a.m.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/0001396814-24-000026-index.htm
- Executive change
  Charles A. Reinhart, III departed as Chief Financial Officer at Pacira BioSciences, Inc..
  - Action: will depart
  - Role: Chief Financial Officer
  source text: On February 26, 2024, the Company and Charles A. Reinhart, III, the Company’s Chief Financial Officer, agreed that he will depart the Company, effective September 30, 2024 (the “Transition Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1396814/000139681424000026/0001396814-24-000026-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.